Sequel and Senseonics Launch twiist Insulin Pump with Eversense 365 CGM Nationwide
Sequel Med Tech and Senseonics announced full U.S. availability of the twiist Automated Insulin Delivery System integrated with the Eversense 365 CGM, the world's only one-year continuous glucose monitor, for people with type 1 diabetes.
Manchester, New Hampshire-based Sequel Med Tech and Germantown, Maryland-based Senseonics announced full availability of the twiist Automated Insulin Delivery (AID) System integrated with the Eversense 365 CGM system across the U.S. on February 19, 2026. The integrated system is now being used in real-world care settings and is widely available for people with type 1 diabetes.
Powered by Tidepool, twiist is the first AID system compatible with Eversense 365, the world's only one-year CGM. This combination offers a solution for long-term diabetes management by significantly reducing the burden of frequent sensor changes and re-pairing while maintaining exceptional CGM accuracy.
The companies first struck a deal to integrate technologies in April 2025. They made twiist the first AID system compatible with Eversense 365, the world's first and only one-year CGM. Last month, the companies announced that the first commercial patients received their paired Eversense 365 and twiist systems.
Sequel built its twiist system to represent the next generation of insulin delivery. It measures the volume of insulin delivered and adjusts basal doses to the user's needs, while delivering blockage alerts and more innovative features. Sequel won FDA clearance for twiist in March 2024.
As the first automated insulin delivery system that directly measures the volume of insulin delivered with every microdose, twiist combines adaptability, accuracy, and precision. The system offers the flexibility to address individual dosing needs by automatically adjusting basal insulin delivery via the twiist Loop algorithm (based on the diabetes community-driven Tidepool Loop) using real-time CGM data, and offers unique features like activity presets, the widest glucose target range, and the ability to edit carb entries or meal timing.
twiist is underpinned by its proprietary iiSure Technology which includes checkpoints to help ensure accurate insulin delivery and detect potential blockages up to nine times faster than other pumps. twiist is cleared for people ages six and up with type 1 diabetes, available with a prescription.
Integration with Eversense 365 is an important milestone as it is the only long-term CGM system available, offering 365 days of uninterrupted, reliable glucose readings. It is the most accurate CGM in low glucose ranges where errors can have the greatest impact on patient safety and treatment decisions.
Sequel is committed to offering people with type 1 diabetes greater flexibility and choice in managing their diabetes. Those who use twiist can personalize their diabetes management by choosing between two compatible CGM partners: Senseonics' Eversense 365 or Abbott's FreeStyle Libre 3 Plus sensor, depending on their personal preferences and needs.
Sequel now offers twiist through pharmacy channels with a flexible access model. It allows users to start for $0 in the first month, then pay no more than $50 per month thereafter, without long-term commitments.